The efficacy and tolerability of perampanel and other recently approved anti-epileptic drugs for the treatment of refractory partial onset seizure: a systematic review and Bayesian network meta-analysis

References

• Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011;52:1331-40
   PubMed Web of Science ®Google Scholar
• Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Currents/American Epilepsy Society 2011;11:56-63
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Moore CG. Direct versus indirect comparisons: a summary of the evidence. Int J Tech Assess Health Care 2008;24:170-7
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Guide to Methods of Technology Appraisal. London: National Institute for Clinical Excellence, 2004
   Google Scholar
• Edwards SJ, Clarke MJ, Wordsworth S, et al. Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. Int J Clin Pract 2009;63:841-54
   PubMed Web of Science ®Google Scholar
• Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134, iii-iv
   PubMed Web of Science ®Google Scholar
• Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J 2003;326:472
   PubMed Web of Science ®Google Scholar
• Marson AG, Hutton JL, Leach JP, et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 2001;46:259-70
   PubMed Web of Science ®Google Scholar
• Guekht AB, Korczyn AD, Bondareva IB, et al. Placebo responses in randomized trials of antiepileptic drugs. Epilepsy Behav 2010;17:64-9
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clinical Trials 1996;17:1-12
   PubMedGoogle Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60
   PubMed Web of Science ®Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011;14:429-37
   PubMed Web of Science ®Google Scholar
• David JS, Best NG, Carlin BP, et al. Bayesian measures of model complixity and fit. J Roy Stat Soc B Stat Meth 2002;64:583-639
   Web of Science ®Google Scholar
• Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308-17
   PubMed Web of Science ®Google Scholar
• Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010;51:958-67
   PubMed Web of Science ®Google Scholar
• Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443-53
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1817-24
   PubMed Web of Science ®Google Scholar
• French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011;76:1555-63
   PubMed Web of Science ®Google Scholar
• Porter RJ, Partiot A, Sachdeo R, et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007;68:1197-204
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Gabbai AA, Hufnagel A, et al. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res 2010;89:278-85
   PubMed Web of Science ®Google Scholar
• Elger C, Halasz P, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009;50:454-63
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Lopes-Lima J, Almeida L, et al. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009;120:281-7
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012;79:589-96
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013;54:117-25
   PubMed Web of Science ®Google Scholar
• Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:1408-15
   PubMed Web of Science ®Google Scholar
• Sancho J, Ivanez V, Molins A, et al. Changes in seizure severity and quality of life in patients with refractory partial epilepsy. Epilepsy Behav 2010;19:409-13
   PubMed Web of Science ®Google Scholar
• Vlooswijk MC, Jansen JF, Reijs RP, et al. Cognitive fMRI and neuropsychological assessment in patients with secondarily generalized seizures. Clin Neurol Neurosurg 2008;110:441-50
   PubMed Web of Science ®Google Scholar
• Ficker DM, So EL, Shen WK, et al. Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology 1998;51:1270-4
   PubMed Web of Science ®Google Scholar
• Gaitatzis A, Sander JW. The mortality of epilepsy revisited. Epileptic Disorders 2004;6:3-13
   PubMed Web of Science ®Google Scholar
• Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-24
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: the European experience. Epilepsia 1997;38(Suppl 1):S28-30
   PubMed Web of Science ®Google Scholar
• Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996;46:1684-90
   PubMed Web of Science ®Google Scholar
• Faught E. Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United States trial experience. Epilepsia 1997;38(Suppl 1):S24-7
   PubMedGoogle Scholar
• Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol 2011;64:1187-97
   PubMed Web of Science ®Google Scholar
• Martyn-St James M, Glanville J, McCool R, et al. The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison. Seizure 2012;21:665-78
   PubMed Web of Science ®Google Scholar
• Costa J, Fareleira F, Ascencao R, et al. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia 2011;52:1280-91
   PubMed Web of Science ®Google Scholar
• Chung SS. Lacosamide: new adjunctive treatment option for partial-onset seizures. Expert Opin Pharmacother 2010;11:1595-602
   PubMed Web of Science ®Google Scholar